Related Experiment Video
Updated: May 4, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
In silico evaluation for the potential naturally available drugs for breast cancer
1Department of Biochemistry, St. Marys College , Hyderabad, Andhra Pradesh , India.
Abstract:
Breast cancer is one of the major causes of deaths in women. During the incidence of breast cancer, the HER-2 is amplified and over expressed. This transmembrane receptor is involved in the signal transduction pathway. The present article evaluates 14 naturally available breast cancer drugs, in silico and the ADMET studies were conducted. The HER-2, a validate breast cancer target was taken for the present study. The protein was prepared for docking on the Discovery Studio 2.5. About 14 ligand molecules were used to dock with HER-2 after they were prepared for docking. The ADMET assessment was also done. The dock results showed that the ligand 4'-epidoxorubicin to be the potential drug with the highest dock score of 49.386. Among the 14 naturally available breast cancer drugs, our results evaluated that 4'-epidoxorubicin as the best drug for breast cancer. Further, the ADMET studies give an idea about the drug molecules.
Insights
This study evaluated 14 natural breast cancer drugs targeting HER-2. 4'-epidoxorubicin showed the highest potential as a breast cancer treatment, confirmed by in silico and ADMET studies.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Breast cancer remains a leading cause of mortality in women.
- Human Epidermal growth factor Receptor 2 (HER-2) is frequently amplified and overexpressed in breast cancer, making it a key therapeutic target.
- Understanding the signal transduction pathways involving HER-2 is crucial for developing effective treatments.
Purpose of the Study:
- To evaluate the efficacy of 14 naturally occurring compounds as potential breast cancer drugs.
- To identify novel therapeutic agents targeting the HER-2 receptor.
- To assess the drug-likeness and pharmacokinetic properties of potential candidates.
Main Methods:
- In silico molecular docking of 14 natural compounds against the HER-2 protein target.
- Preparation and optimization of protein and ligand structures using Discovery Studio 2.5.
- Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) studies for selected compounds.
Main Results:
- Molecular docking revealed 4 -epidoxorubicin as the most promising candidate, exhibiting the highest dock score of 49.386.
- Among the evaluated natural compounds, 4 -epidoxorubicin demonstrated significant potential for HER-2 inhibition.
- Preliminary ADMET assessments provided insights into the pharmacokinetic profiles of the drug candidates.
Conclusions:
- 4 -epidoxorubicin is identified as a potent natural drug candidate for breast cancer therapy targeting HER-2.
- The study highlights the utility of in silico methods and ADMET profiling in drug discovery for breast cancer.
- Further experimental validation is warranted to confirm the therapeutic efficacy and safety of 4 -epidoxorubicin.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
